Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data

Vishnu Murthy; Andrew F. Voter; Kathleen Nguyen; Martin Allen-Auerbach; Lucia Chen; Sydney Caputo; Elisa Ledet; Abraham Akerele; Abuzar Moradi Tuchayi; Courtney Lawhn-Heath; Tingchang Wang; Michael A. Carducci; Martin G. Pomper; Channing J. Paller; Johannes Czernin; Lilja B. Solnes; Thomas A. Hope; Oliver Sartor; Jeremie Calais; Andrei Gafita

doi:10.2967/jnumed.124.267816

Research ArticleClinical Investigation

Efficacy and Toxicity of [¹⁷⁷Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data

Vishnu Murthy, Andrew F. Voter, Kathleen Nguyen, Martin Allen-Auerbach, Lucia Chen, Sydney Caputo, Elisa Ledet, Abraham Akerele, Abuzar Moradi Tuchayi, Courtney Lawhn-Heath, Tingchang Wang, Michael A. Carducci, Martin G. Pomper, Channing J. Paller, Johannes Czernin, Lilja B. Solnes, Thomas A. Hope, Oliver Sartor, Jeremie Calais and Andrei Gafita

Journal of Nuclear Medicine November 2024, 65 (11) 1740-1744; DOI: https://doi.org/10.2967/jnumed.124.267816

Vishnu Murthy

1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Andrew F. Voter

2Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kathleen Nguyen

1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Martin Allen-Auerbach

1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lucia Chen

3Department of Medicine Statistics Core, David Geffen School of Medicine at UCLA, Los Angeles, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sydney Caputo

4Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Elisa Ledet

4Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Abraham Akerele

4Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Abuzar Moradi Tuchayi

5Department of Radiology and Biomedical Imaging, University of California, San Francisco, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Courtney Lawhn-Heath

5Department of Radiology and Biomedical Imaging, University of California, San Francisco, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Tingchang Wang

6Department of Biostatistics, Johns Hopkins School of Medicine, Baltimore, Maryland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael A. Carducci

7Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Martin G. Pomper

2Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Channing J. Paller

7Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Johannes Czernin

1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lilja B. Solnes

2Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland;

8Johns Hopkins Theranostics Center, Baltimore, Maryland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Thomas A. Hope

5Department of Radiology and Biomedical Imaging, University of California, San Francisco, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Oliver Sartor

4Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jeremie Calais

1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Andrei Gafita

2Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland;

8Johns Hopkins Theranostics Center, Baltimore, Maryland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Individuals

Non-Member Login

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 65, Issue 11

November 1, 2024

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Efficacy and Toxicity of [¹⁷⁷Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data

Journal of Nuclear Medicine Nov 2024, 65 (11) 1740-1744; DOI: 10.2967/jnumed.124.267816

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Efficacy and Toxicity of [¹⁷⁷Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data

Journal of Nuclear Medicine Nov 2024, 65 (11) 1740-1744; DOI: 10.2967/jnumed.124.267816

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Keywords

mCRPC
PSMA PET
VISION
EAP

Main menu

User menu

Search

Efficacy and Toxicity of [¹⁷⁷Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data

Individuals

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords